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Abstract
The monoclonal antibodies, 9.2.27 against human melanoma cell lines and WM53 against leukemia cell lines, were
conjugated with cyclic anhydride gadolinium-diethylenetriaminepenta-acetic acid (Gd-cDTPAa) and used as tumor-
specific contrast agents in magnetic resonance imaging (MRI). The data indicate that Gd-DTPA-9.2.27 in solution
decreased the T1 relaxation of water protons at 7.0 Tesla (300 MHz) in direct proportion to the gadolinium
concentration, and this effect was greater than in Gd-DTPA solutions. These conjugates show high specificity for
melanoma and leukemia cell lines. T1 relaxation time at 7.0 Tesla, measured for the melanoma cell line (MM-138) and
leukemia cell line (HL-60) after incubation at 37 C for 4 hr, were significantly decreased (approximately 25%)
relative to controls. The gadolinium concentration in cells and washing solutions was measured by inductively coupled
plasma atomic emission spectroscopy (ICP-AES). A linear relationship was observed between T1 relaxation rates and
gadolinium concentrations obtained by ICP-AES. The ICP-AES results showed no gadolinium uptake in the non-
targeted HT-29 colorectal cancer cells.
Key words  magnetic resonance imaging, gadolinium,
monoclonal antibody, and cancer.
Introduction
The development of contrast agents with tissue-specific
enhancement deserves considerable attention because of
their potential in earlier and improved diagnosis and in
possible therapy. One approach to increasing the specificity
of MR image contrast is to use a monoclonal antibody (mab)
coupled with contrast agent Gd-DTPA (1-4). The use of
antibodies for diagnostic imaging in the search for tumors
was established in 1953 by Pressman and Korngold (5), who
imaged a tumor in a rat using 131I-labelled polyclonal
antibodies. The development of monoclonal antibodies (6)
offers the possibility of defined product for routine
diagnosis. Mach et al (7) published the first description of
clinical studies with monoclonal anti-CEA antibodies in
1981.
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MR imaging has three major advantages compared to
scintigraphy regarding the application of monoclonal
antibodies (mab) as a tumor-specific contrast agent. First,
MR imaging avoids the handling of radioisotopes by the use
of naturally occurring paramagnetic metals. Second, in MR
imaging, the tissue can be imaged before and after
administration of the imaging contrast agent. The third
advantage of MR imaging is its higher spatial resolution,
which permits better localization and differentiation of the
tumor (4).
Gadolinium is the element of choice for MR image
enhancement due to its high number of unpaired electron
(8). The first in-vivo studies with the gadolinium-labeled
monoclonal antibody were performed by Unger et al (1) and
by Andersen-Berg et al (2). Gadolinium was attached to the
monoclonal antibody via the coupling of anhydride
derivatives of DTPA. These studies showed that 100-1,000
gadolinium ions are needed per antibody conjugate are
required to achieve concentrations in the tumor sufficient for
signal enhancement in MR imaging (8). Curtet et al (3)
coupled mab to gadolinium using cyclic anhydride method
and demonstrated that T1 relaxation of water protons
decreased significantly (by 15%) with mab 19-9, which
recognizes human colon adenocarcinoma. They used a 25-
Gd-DTPA-antibody conjugate to reduce the effect of
immunologic reactivity. Implanted human colon carcinoma
Australas. Phys. Eng. Sci. Med. Vol. 25, No 1, 2002 Shahbazi-Gahrouei et al  In vitro studies of gadolinium-DTPA
32
tumors in mice have been successfully imaged by using
monoclonal antibodies with a large number of Gd-DTPA
molecules attached (9). In recent years, in vivo studies of
Gd-DTPA-mab and Gd-porphyrins as MR imaging contrast
agents for melanoma detection was investigated in nude
mice by author and colleges (10).
Recently, research efforts concentrated on maximizing
the delivery of specific T1 agents to tumors. Gohr-Rosental
et al (4) reported successful studies of Gd-DTPA
monoclonal antibody in subcutaneous tumor in nude mice.
One year later, Matsumura et al (11) observed MR imaging
contrast enhancement by Gd-DTPA-monoclonal antibody in
9L glioma rats. However, the number of Gd attached to the
DTPA-protein complex, the effect of chelation on antibody
specificity, and the Gd-DTPA-antibody stability is
problematic.
The aims of this study are to investigate the conjugation
of gadolinium with monoclonal antibody and to observe the
contrast enhancement effect of Gd-DTPA-mab as an MR
imaging contrast agent. To this end, all samples were tested
by inductively coupled plasma atomic emission
spectroscopy (ICP-AES) to determine the gadolinium
concentration. The effect of the Gd-DTPA-mab on the in
vitro conditions and its relaxivity was also investigated.
Materials and methods
Mab 9.2.27 for melanoma
The monoclonal antibody 9.2.27 (specific for melanoma
cell line MM-138) was supplied through the Royal
Newcastle Hospital. This antibody has a high specificity for
all human melanoma cell surfaces and frozen sections of
fresh surgical melanoma specimens (12, 13) because of the
strong antigenic expression of a 250-kilodalton N-linked
glycoprotein and a high molecular weight proteoglycan
component larger than 400-kilodaltons.
Mab WM-53 for leukemia
The murine monoclonal antibody WM53, specific for
leukemia cell line HL-60, was supplied at Westmead
Hospital.
DTPA-mab conjugation
Both conjugates (DTPA-9.2.27 and DTPA-WM53)
were prepared in a similar manner. The mab was covalently
bound to the DTPA chelating agent (14). Cyclic anhydride
DTPA (cDTPAa, 0.1 mg) was dissolved in chloroform (1
ml) and was degassed under a stream of nitrogen for 1 hr.
9.2.27 (2 mg, 1ml) and WM53 (3 mg, 1ml) antibodies
solution was added and the mixture incubated at 0 C for 45
minute. Mole ratio of DTPA to 9.2.27 was 20:1. The
resulting solution was loaded on to a PD-10 column,
sephadex GM-25, (101 cm, Pharmacia, Biotech) and eluted
with 0.5 M sodium acetate (pH 5.5), collecting 2 ml. The
concentration of 9.2.27 and WM53 in the final solution was
determined by protein estimation as 2 mg/ml and 3 mg/ml,
respectively.
Gd-DTPA-mab
The following is an adopted method used for insertion
of gadolinium (3,11) and is the optimized procedure.
Gadolinium(III) chloride hexahydrate (1.8 mg) was
dissolved in 1 ml of distilled water. To this solution, DTPA-
9.2.27 (4 mg, 2 ml) and DTPA-WM53 (6 mg, 2 ml) was
added separately. The pH was adjusted to 5 by addition of 1-
M sodium acetate. After stirring for 1 hr at room
temperature, the solution was added to a PD-10 column and
eluted with sodium chloride (0.15 M, pH = 5), collecting 1
ml fractions. The fourth and fifth fractions were combined
to yield 2 ml of pure gadolinium conjugates. The
gadolinium concentration was (protein estimate = 2 mg/ml,
[Gd] = 0.47 mM) in conjugate of Gd-DTPA-9.2.27 solution
and (protein estimate = 3 mg/ml, [Gd] = 0.51 mM) in
conjugate of Gd-DTPA-WM53 solution.
Protein estimation and Gd attachment to conjugate
All column fractions from the chromatography column
(purification) were collected and an aliquot of each fraction
was analyzed for concentration of protein and gadolinium.
Concentration of protein measured by spectrophotometer
UV absorption at 280 nm (SPECTRAmax 250, USA) using
standard protein estimation method. An aliquot was
examined by both ICP-AES and MR imaging to determine
the final amount of coupled protein-gadolinium and
gadolinium concentration in the conjugates. The fourth and
fifth fractions from the column were combined as a Gd-
DTPA-mab tumor specific agent for further studies.
Gadolinium-hematoporphyrin
Gadolinium(III) nitrate hexahydrate (0.30 g, 0.66 mmol)
was dissolved in 2 ml of distilled water. Hematoporphyrin
([8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-21H,23H-
porphine-2,18-dipropionic acid]) powder (0.40 g, 0.66
mmol) was suspended in 2 ml of distilled water and was
added to the gadolinium solution and refluxed until the
solution become homogeneous. The solution was allowed to
cool to room temperature. This solution was reduced to 1 ml
under reduced pressure with heating. The resulting white
solid was filtered, washed carefully with ice-cold water (2 
0.5 ml) and dried in the oven at 80 ºC. The yield was 0.11 g
(21%).
T1 relaxation times and relaxivity measurements
T1 relaxation times of samples was measured using an
inversion recovery (IR) pulse sequence technique using a
7.0 T Varian UNITY Plus (Varian Associated Inc., CA) with
a vertical Oxford Instruments magnet of bore size 89-mm
using the saddle coil (DOTY Scientific Instruments). The
values of TI=200 ms, TE=30 ms and TR=1000 ms was used
for relaxation times measurements. The increment of the
water proton relaxation rate per unit concentration of the
paramagnetic contrast agent is called the relaxivity (R1) and
is calculated according to the following formula:
1/Ti  = 1/Ti (control) + Ri C
where i = {1,2}, Ti is relaxation time of sample, Ti (control) is
relaxation time of blank or the system before addition of
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contrast agent, C is concentration of paramagnetic contrast
agent or Gd, and Ri is the relaxivity (mM
-1 s-1). The
measurement was performed in aqueous solution of Gd-
DTPA-mab.
Conjugation of Gd-DTPA-mab with cells
The specificity of the monoclonal antibody conjugates
was tested with the melanoma and leukemia cell lines. The
following procedure was performed using solutions of
gadolinium in discrete compounds (GdCl3, Gd-DTPA, and
Gd-H) and conjugates antibody (Gd-DTPA-WM53 and Gd-
DTPA-9.2.27).
The melanoma cell line (MM-138, 2.5106 cells/ml, St.
George Hospital) and leukemia cell line (HL-60, 2.5106
cells/ml, St. George Hospital) were incubated with Gd-
DTPA-9.2.27 and Gd-DTPA-WM53 for 4 hr at 37 C,
respectively. Colorectal cell line (HT-29) was used as a non-
specific control. The incubation time for all contrast agents
was chosen as 4 hr, sufficient time for saturated attachment
of agents to the cell membranes. After incubation, all the
cells were washed twice with PBS/2%FCS, followed by
centrifugation, then resuspended in PBS/2%FCS solutions.
All samples and solutions were tested by both ICP-AES and
NMR.
Determination of gadolinium concentration by ICP-AES
The gadolinium content was measured based on an acid
digestion procedure using ICP-AES (Applied Research
Laboratory, UK) instrument according to the method of
Tamat et al (15). Briefly, to a weighed sample of tissue (50-
100 mg) in a polyethylene vial, 0.3 ml of 72% perchloric
acid was carefully added and the contents swirled to mix.
Then 0.6 ml of 32% hydrogen peroxide was added and the
vials placed in the shaking bath for 5 hr at 25 C. At this
stage, the vial contents were cleared and colorless. The
samples were diluted with 3 ml of distilled water and
filtered through a 0.45 m Millipore filter (Altech
Association Inc., Australia) before being introduced into the
ICP-AES. The 342.249 nm atomic emission line of
gadolinium was chosen for the ICP-AES analysis. A
separate solution of GdCl3 (0.1 mg/ml) was prepared
containing perchloric acid and hydrogen peroxide, but
without the heating and filtering steps.
Results
Effect of Gd-DTPA-9.2.27 on relaxation time T1
Figure 1 and Table 1 show the effect of Gd-DTPA-mab
on water relaxation time T1 at room temperature. In these
experiments, the concentration of DTPA-9.2.27 was kept
constant (0.01 mM), and the amount of gadolinium
concentration bound to DTPA-9.2.27 was varied. As this
figure shows increases in the number of bound gadolinium
ions resulted in a decrease in T1 relaxation time. At high
concentrations of gadolinium, the effect on T1 relaxation
time was reduced (Fig. 1).
Figure 1. Effect of gadolinium insertion into DTPA-9.2.27 on T1








0.01 0.0 3003  45 0.33  0.05
0.01 0.1   500  12      2  0.05
0.01 0.5   121  8.2   8.3  0.1
0.01 1.0     50  6    20  0.4
0.01 3.0  17.5  1.4    57  0.5
0.01 6.0    9.8  0.5   102  0.5
0.01 7.5    7.9  0.6   126  0.9
0.01 10.0    6.8  0.4   147  0.8
Table 1. 1/T1 relaxation rates of water for different number of
gadolinium bound to Gd-DTPA-9.2.27 in aqueous solution.
Gadolinium ions inserted by reaction of DTPA-9.2.27 with GdCl3.
Relaxivity of Gd-DTPA-9.2.27
The T1 relaxation rate of the solution of Gd-DTPA-
9.2.27 was measured to be 13.5 s-1 (T1 = 0.074 s) at a
concentration of gadolinium of 0.47 mM. The T1 relaxation
rate of a solution of Gd-DTPA of the same concentration
was 0.55 s-1. This relaxivity was higher than that of
Gd-DTPA alone (8). However, Gd-DTPA-9.2.27 was more
effective than Gd-DTPA (3.7 mM-1 s-1) in reducing
relaxation times.
Determination of gadolinium uptake by Melanoma cells
(MM-138)
T1 relaxation time and gadolinium concentration
measurements performed using discrete contrast agents
GdCl3, Gd-DTPA, Gd-H, and conjugates antibody Gd-
DTPA-9.2.27 specific for melanoma cell line with MM-138
(2.5106 cells/ml). Colorectal cell line, HT-29, (2.5106
cells/ml) was used as non-specific target cells for 9.2.27
antibody. Unlabelled conjugates were used as negative or
control. To determine the amount of gadolinium which the
cells would not bind, samples of washing solutions were
collected and analyzed by both MR imaging and ICP-AES.
















Australas. Phys. Eng. Sci. Med. Vol. 25, No 1, 2002 Shahbazi-Gahrouei et al  In vitro studies of gadolinium-DTPA
34
Contrast agent Wt. of Gd (mg) in
cells*
Wt. of Gd (mg) in
washing solution*
T1 (s) in cells Initial [Gd] (mM)
GdCl3 0.000  0.002 0.144  0.012 2.06  0.01 1
Control 0.000  0.002 0.000  0.002 1.80  0.02 0
Gd-DTPA 0.052  0.003 0.097  0.006 1.55  0.01 1
Gd-H 0.082  0.004 0.064  0.005 1.40  0.04 1
Gd-DTPA-9.2.27a 0.071  0.004 0.012  0.003 1.32  0.03 0.5
Table 2. The amount of  gadolinium  contrast agents  and  T1  relaxation  time  in  melanoma  cell  line  (MM-138)  and  washing  solution.
a. Solution obtained from chromatography column.          *. Data obtained from five measurement.
Figure 2. Relationship between T1 relaxation rates and
gadolinium concentrations in melanoma (MM-138), using MR
imaging and ICP-AES measurement respectively.
washing solutions was measured by ICP-AES and MR
imaging is shown in Table 2.
For GdCl3, 100% of this material was found in the
washing solution. This indicated that, during incubation,
GdCl3 remained in solution and did not become fixed to the
melanoma cells. For the monoclonal antibody conjugate,
Gd-DTPA-9.2.27, 85% of this material was taken up by (or
become attached to) the cell during incubation. Gd-DTPA
showed some uptake into the melanoma cell membranes
with incubation, however, the amount was significantly
lower than that of the monoclonal antibody conjugate. Gd-
H showed a greater uptake into the melanoma cells
compared to Gd-DTPA, but still not as high as the uptake
of the antibody conjugate.
The T1 relaxation times of the intact cells reflected the
amount of gadolinium absorbed into or fixed to the cell
membranes. As Table 2 shows the highest amount of
gadolinium and the lowest T1 relaxation time is observed
for the specific conjugated monoclonal antibody,
Gd-DTPA-9.2.27. Figure 2 shows the graph of T1
relaxation rates plotted against the gadolinium quantity.
Table 3 shows the percentage of gadolinium distributed
between cells and washing solutions, as measured by ICP-
AES. The specific conjugate added to melanoma cells
compared to controls shows a significant variation of 25%
in the T1 relaxation time.
Sample Cell lines %[Gd] in cells* %[Gd] in washing
solutions*
T1 (s) of cells
Gd-DTPA-9.2.27a MM-138 85  14 15  5 1.32  0.03
Gd-DTPA-9.2.27a HT-29 0.0  2 100  16 2.50  0.06
GdCl3 MM-138 0.0  1 100  14 2.06  0.01
Gd-DTPA MM-138 35  3 65  7 1.55  0.02
Gd-H MM-138 56  4 44  6 1.40  0.04
Control MM-138 0.0  1 - 1.80  0.02
Control HT-29 0.0  2 - 2.45  0.06
PBS/2%FCS - 0.0  1 - 3.65  0.05
Table3. Distribution of gadolinium between cells and washing solutions for MM-138 and HT-29 cells when treated with different contrast
agents.          a. Solution obtained from chromatography column.        *. Data obtained from five measurement.
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Leukemia cell uptake of contrast agents
Several studies have assumed that the decrease of T1
relaxation time in melanoma is attributed to the presence of
melanin (17-19). To test this assumption and to ascertain
whether decreases in T1 values may have a more general
usefulness as tumor-specific agent, the specificity of the
monoclonal antibody conjugate Gd-DTPA-WM53 was
investigated with leukemia cell line (HL-60). Colorectal
cell line (HT-29) was also used as a non-specific for this
conjugate. The procedure and conditions was similar to the
previous section. The results of T1 relaxation times and the
amount of gadolinium in cells and in washing solution are
shown in Table 4. The effect of shortening relaxation time
were observed in leukemia cell for both specific Gd-DTPA-
WM53 (25%) and Gd-H (21%). It can be seen that the
decreases in T1 values when using Gd-DTPA-mab
compared with Gd-DTPA are approximately 12% for
leukemia and 15% for melanoma. In order to compare the
mab-conjugate and other contrast agents, incubation of
leukemia cells in the discrete contrast agents GdCl3,
Gd-DTPA, and Gd-H was also tested. HL-60 with no
incubation with contrast agents was used as control.
The T1 relaxation times of the cells and the amount of
gadolinium attached to the leukemia cell are shown in
Table 4. The relationship between relaxation rates (1/T1)
and gadolinium content of cells is presented in Figure 3.
This graph is consistent with the observations made for the
T1 values of melanoma cells treated contrast agents. A
relationship exists but the difference in relaxivity of the
complexes does not allow for a higher degree of linearity in
Figure 3. Relationship between T1 relaxation rates and
gadolinium concentrations in leukemia (HL-60), using MR
imaging and ICP-AES measurement respectively.
the graph.
Results in Table 5 for gadolinium content are presented
as a percentage of the initial gadolinium quantity added to
the leukemia cells before incubation. The highest amount of
gadolinium (78%) into the cells was achieved by
monoclonal antibody conjugate Gd-DTPA-WM53, and as
expected the smallest amount of gadolinium concentration
(22%) in washing solutions observed, approving that the
most of gadolinium complex was found into the cells.
Again for the non-specific target cell, HT-29, and HL-60 as
negative control, there was no gadolinium in cells and most
of gadolinium was observed in the washing solutions.
Contrast agent Wt. of Gd (mg) in
cells*
Wt. of Gd (mg)
in washing solution*
T1 (s)          in cells Initial [Gd] (mM)
GdCl3 0.000  0.002 0.154  0.010 2.32  0.01 1
Control 0.000  0.002 0.000  0.002 2.40  0.01 0
Gd-DTPA 0.045  0.003 0.100  0.014 2.03  0.03 1
Gd-H 0.072  0.003 0.078  0.009 1.90  0.04 1
Gd-DTPA-WM53a 0.061  0.003 0.017  0.003 1.80  0.04 0.5
Table 4. The amount of gadolinium material in leukemia cell line (HL-60) and washing solution.     a: Solution obtained from
chromatography column.        *. Data obtained from five measurement.
Sample Cell lines %[Gd] in cells %[Gd]    in washing
solution
T1 (ms) of cells
Gd-DTPA-WM53a HL-60 78  4 22  3 1.80  0.04
Gd-DTPA-WM53a HT-29 0  2 100  14 2.50  0.06
GdCl3 HL-60 0  2 100  10 2.32  0.01
Gd-DTPA HL-60 31  2 69  6 2.03  0.03
Gd-H HL-60 48  3 52  4 1.90  0.04
Control HL-60 0  2 - 2.40  0.02
Control HT-29 0  1 - 2.45  0.06
PBS/2%FCS - 0  1 - 3.65  0.05
Table 5. Distribution of gadolinium between cells and washing solutions for HL-60 and HT-29 cells when treated with different
contrast agents.          a. Solution obtained from chromatography column.
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Discussion
Several approaches might be considered to increase
gadolinium concentration in the tumor. It is possible to
increase the amount of DTPA coupling per molecule of
mab, although with a corresponding loss of
immunoreactivity (1,3,10). In order to improve the quality
of imaging and increase efficacy of therapy using
radiometal-labeled mab, cyclic DTPA anhydride has been
developed and well characterised. Hnatowich et al (14)
reported a successful conjugation of DTPA to human
albumin (18.8 mg/ml, 2.8  10-4 M) using cDTPAa as an
acylating agent. In this work this agent was used to
conjugate DTPA to a practical concentration (300 g/ml) of
monoclonal melanoma antibody (9.2.27). The choice of
anhydride is sensible. Cyclic DTPA anhydride forms one of
the strongest chelates known for a large number of metals
(14).
ICP-AES measurements
Although several methods are available in measuring
trace metals of tissue, the ICP-AES method was found to
highly accurate and sensitive for the analysis of gadolinium
(19).
MR imaging of samples of Gd-DTPA in HL-60 cells
demonstrated that concentration of gadolinium necessary
for significant enhancement on the 7.0 Tesla magnetic field
strength was 0.01 mM (Table 5). This concentration of
gadolinium is approximately the same as that required for
gadolinium in the form of Gd-DTPA unattached to protein
and roughly corresponds to that reported by other
researchers as giving significant enhancement on MR
imaging (10,20).
T1 relaxation time measurements
Before assessing the potential clinical value of
gadolinium coupled monoclonal antibody for MR imaging
of tumors, it was necessary to ensure that the antibody did
not modify the paramagnetic properties of gadolinium in
the complex. The studies performed on aqueous solutions
of Gd-DTPA confirmed that T1 is inversely proportional to
the concentration of the paramagnetic agent. When
gadolinium was conjugated with the antibody by means of
the chelator cDTPAa, a linear relation was observed
between the reversal of T1 relaxation time and the
gadolinium concentration.
The effect of covalently conjugating one (or more)
gadolinium ions to a slowly tumbling macromolecule such
as an antibody or synthetic protein is to increase the
correlation time c and enhance relaxivity. Monoclonal
antibodies labeled with gadolinium have been considered in
order to effectively target cancer cells with the contrast
agent to.
The effect of gadolinium on the relaxation time was
greater when it was coupled with antibody. In fact,
gadolinium binding on this macromolecule caused an
increase in the correlation time (c) of the paramagnetic
complex, thus leading to an increase in the speed of
relaxation (20, 21). This effect arises when a paramagnetic
ion or complex is bound to a protein or macromolecular
because of an increased r, and hence c. The rotational
correlation time r increases as a function of molecular
volume and leads to increased relaxivity.
The uptake of Gd-DTPA-WM53 in leukemia cells was
measured to test the assumption that decreases in T1 values
in melanoma cells is due to the presence of melanin. The
results for leukemia show similar reduction of T1 values to
those for melanoma cells so cannot be ascribed to melanin.
Of course, differences may also arise because antibodies
have different affinity to conjugation with DTPA and
different specificity for target cells.
Melanoma cell uptake of contrast agent
The results of incubation of melanoma cells with
discrete compounds and conjugates monoclonal antibody
contrast agents showed that no was gadolinium uptake
using GdCl3. This also showed that any gadolinium
released from their complexes either in the discrete
compounds or the antibody conjugate will end up in the
washing solutions. Therefore, any gadolinium found inside
the cell lines must have been delivered to the cell
membrane as the intact gadolinium complex. The
assumption was made that the volume of the melanoma
cells has not changed during their incubation with the
contrast agents. Hence, the amount of gadolinium reflects
the concentration of gadolinium in the treated cells. The
lack of any uptake by HT-29 of this material was consistent
with this finding the antibody remaining selective to
melanoma. These results are in good agreement with in
vivo findings in nude mice (10).
The relationship between relaxation rates and
gadolinium concentration is well-established in
homogeneous solutions and is used extensively in this work
(21). However, the extension of this relationship for cells
and tissue has great potential. If the relationship between
relaxation rates and gadolinium concentration is valid in
tissues and biological media, then the concentration of
contrast agent could be determined in situ. This work
establishes that a relationship exists between the T1
relaxation rates of melanoma cells and gadolinium
concentrations.
Figure 2 showed the existence of a relationship
between relaxation rates and gadolinium concentration, but
it is clearly not high linear. This non-linearly is due to the
differences in relaxivity between the complexes. The higher
than expected T1 value for melanoma cells treated with Gd-
DTPA-9.2.27 arise from its higher relaxation rate compared
to Gd-DTP. This result is also consistent with the
complexes remaining intact inside the melanoma cell
membrane after incubation. More information is required to
enable gadolinium concentration in tumor cells to be
determined in this manner.
Leukemia cell uptake of contrast agent
The results of incubation of leukemia cells with
discrete compounds and conjugates monoclonal antibody
contrast agents showed the specificity of Gd-DTPA-WM53
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tumor-specific contrast agent and its potential as a MR
imaging probe for the detection of leukemia.
For Gd-DTPA some gadolinium (31%) attachment was
observed in the cells, but most (69%) was found in washing
solutions. This result was consistent with the observation
for melanoma for which 65% of gadolinium was found in
washing solution. The results in Table 5 also showed that
for Gd-H approximately half of the amount of gadolinium
was found into the leukemia cell.
Both measurements in washing solutions and cells
using ICP-AES and T1 relaxation times confirmed the high
specificity of the specific conjugates for targeted cells
(Gd-DTPA-9.2.27 for melanoma and Gd-DTPA-WM53 for
leukemia) compared to controls. The results also
demonstrated that monoclonal antibody conjugates with
Gd-DTPA have the potential to deliver these agents to the
target tumor. No gadolinium was detected for non-specific
colorectal (HT-29) cells for both antibody conjugates and
all gadolinium was found in washing solutions. Differences
between relaxation rates of melanoma and leukemia cells
arise from differences in the type of cells and antibodies.
Conclusions
Specific targeting of MR imaging contrast agents
demands a detailed knowledge of the properties of the agent
used. For GdCl3, gadolinium was not detected in the cancer
cells and all gadolinium was found in washing solutions.
For Gd-DTPA and Gd-H, some gadolinium was attached to
the cells. However, a larger fraction of gadolinium complex
was observed in washing solutions.
A 25% reduction T1 relaxation time was observed in
both melanoma and leukemia cell lines for specific
conjugated mab compared to controls. This was confirmed
by observation of gadolinium by ICP-AES in the acid
digested cells. While the relationship between contrast
agent concentration and relaxation rates of both melanoma
and leukemia cell lines is established, its extension into
tumours and biological media is not as clear. Nevertheless,
this technique has potential for the non-invasive in vivo
determination of gadolinium concentration.
As results showed, the smallest T1 relaxation time,
reflecting the highest gadolinium accumulation was
observed for both specific conjugated monoclonal
antibodies (Gd-DTPA-9.2.27 for melanoma and Gd-DTPA-
WM53 for leukemia). This is because the monoclonal
antibody binds the gadolinium to the cell membrane and/or
internalizes the gadolinium into the cell membranes. As the
distribution volume increases, the tissue concentration of
contrast agent increases, which can result in reducing their
relaxation times.
These results indicates that Gd-DTPA-9.2.27 and Gd-
DTPA-WM53 may have affinity to their specific cancer
cells, indicating that these monoclonal antibody conjugates
are potential MR imaging contrast agents for detection of
cancer at early stages. Gd-H also has a similar potential
application as a tumor-specific MR imaging contrast agent.
The findings of this study can be summarized as
follows: Firstly, The optimal measures of the conjugation of
DTPA anhydride and monoclonal antibody were as follows:
pH = 5.5, cyclic DTPA anhydride/antibody = 201. In the
conventional labeling method, the ratio of attached chelates
to monoclonal antibody is usually >1 in order to provide
enough chelating groups for a good labeling yield.
Secondly, The data indicate that Gd-DTPA-9.2.27 in
solution decreased the T1 relaxation of water protons at 7.0
Tesla (300 MHz) in direct proportion to the gadolinium
concentration, and this effect was greater than in Gd-DTPA
solutions.
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